Hexagon Nutrition IPO: India's Only Holistic Pure-Play Nutrition Company Taps Markets – Should You Subscribe?

Hexagon Nutrition IPO: India's Only Holistic Pure-Play Nutrition Company Taps Markets – Should You Subscribe?

Price band set at Rs 42–45 per share; IPO opens June 05, 2026, closes June 09, 2026, tentative listing June 12, 2026 (NSE & BSE).

At a Glance

Company and Its Business Operations

Hexagon Nutrition Limited was originally incorporated as 'Hexagon Chemoils Private Limited' under the Companies Act, 1956 on May 27, 1993, renamed 'Hexagon Nutrition Private Limited' in 2019, and converted to a public limited company on October 14, 2021. The Company is headquartered at Andheri (West), Mumbai, Maharashtra.

The Company is a differentiated, research-oriented pure-play nutrition company and, per the CARE Report, the only holistic nutrition player in India that spans the entire spectrum from micronutrient premixes to therapeutic and clinical products. It is also one of the largest premix players in India, supplying customised vitamin and mineral premixes to leading Indian and multinational FMCG companies, and one of the largest licensed suppliers of Micronutrient Powders (MNPs) under UN programmes.

Its product portfolio operates across three segments: (i) branded wellness and clinical nutrition products (B2C) under brands PENTASURE, OBESIGO, PEDIAGOLD, and NUTRONE; (ii) premix formulations (B2B2C) supplying global beverage companies, dairy cooperatives, and FMCG manufacturers; and (iii) Therapeutic Nutrition — Ready-to-Use Foods (RUFs) and Micronutrient Powders (MNPs) — for UN agencies, foreign governments, and NGOs addressing malnutrition. Key customers include foreign distributors, UN agencies, government health ministries, and multinational FMCG companies across 75 countries.

The Company operates three manufacturing facilities in India (Nashik in Maharashtra; Chennai and Thoothukudi in Tamil Nadu, both in SEZ zones) and one international unit in Tashkent, Uzbekistan, along with two in-house R&D centres. Revenue grew at approximately 8.01 per cent CAGR from FY23 to FY25.

Industry Outlook

The global nutrition market, as per the CARE Report, stood at USD 599 billion in CY23 and grew to USD 731 billion by CY25 at a CAGR of approximately 10.5 per cent. It is projected to reach USD 1,239 billion by CY30, implying a forward CAGR of approximately 11.1 per cent, driven by rising health awareness, an ageing global population, chronic disease prevalence, and expansion of e-commerce channels.

India's nutrition market represents the primary TAM. It grew from Rs 1,183 billion in CY23 to Rs 1,528 billion in CY25 and is projected to reach Rs 2,814 billion by CY30, implying a CAGR of approximately 13.0 per cent — a meaningfully higher growth rate than the global average and a TAM of approximately Rs 2,81,400 crore by CY30. Three structural demand drivers underpin this trajectory: first, government initiatives such as POSHAN Abhiyaan and FSSAI's food fortification mandate are expanding access to fortified foods and micronutrient products in rural India; second, the country's disease burden — 101 million diabetics, 17 per cent CKD prevalence, and over 80 per cent of the population facing micronutrient deficiencies — is accelerating clinical and therapeutic nutrition adoption; and third, rising fitness awareness, premiumisation trends, and e-commerce penetration are driving urban consumption of protein supplements, functional foods, and clean-label products.

Objects of the Issue

• The IPO is a 100 per cent Offer for Sale (OFS) of up to 3,08,59,704 equity shares of face value Rs 1 each, aggregating approximately Rs 138.87 crore at the upper price band.
   
• Selling shareholders and their OFS quantum: Subhash Purushottam Kelkar (Promoter) — 2,41,88,993 shares; Nutan Subhash Kelkar (Promoter Group) — 36,08,142 shares; Arun Purushottam Kelkar (Promoter) — 15,36,477 shares; Aditya Kelkar (Promoter) — 15,26,092 shares.
   
• The Company will not receive any proceeds from the issue. All net proceeds, after deducting applicable issue expenses and taxes, will accrue entirely to the selling shareholders.
   
• The stated objectives of the offer are to achieve the benefits of listing on BSE and NSE, enhance brand visibility and market presence, and provide liquidity to existing shareholders.

SWOT Analysis

Strengths

• Sole holistic pure-play nutrition company in India offering the full product spectrum from micronutrient premixes to clinical and therapeutic nutrition, per the CARE Report — a competitive moat that larger diversified FMCG peers cannot replicate.
• One of the largest licensed MNP suppliers under UN programmes globally, providing recurring institutional revenue and enhancing regulatory and quality credibility across 75-plus export markets.
• Significant margin expansion: EBITDA margin improved from 6.17 per cent in FY23 to 12.33 per cent in FY25, with further improvement to 14.03 per cent in 9MFY26 — a 790 basis point expansion in under three years.
• Conservative capital structure: Debt-to-equity ratio declined from 0.32 in FY23 to 0.14 in FY25, with total borrowings falling from Rs 51.87 crore to Rs 26.60 crore, providing headroom for organic growth.

Weaknesses

• Revenue concentration risk: the top 10 customers contributed 45.87 per cent of revenue in FY25, with the single largest customer accounting for 12.84 per cent — making the revenue base vulnerable to procurement shifts.
• Operating cash flow was negative at Rs (4.07) crore in 9MFY26 due to significant working capital build-up (trade receivables rose Rs 22.85 crore and inventories rose Rs 27.71 crore during the period), suggesting CFO quality deterioration at higher revenue scales.
• Significant capacity underutilisation: facilities operated at approximately 30 per cent utilisation in FY25 and 28.76 per cent in 9MFY26, limiting fixed-cost absorption efficiency.
• Absolute PAT scale is modest at Rs 24.38 crore for FY25, leaving limited earnings buffer for adverse margin shocks relative to the Rs 497.83 crore market capitalisation sought at the upper price band.

Opportunities

• The India nutrition TAM is projected to grow from Rs 1,52,800 crore (CY25) to Rs 2,81,400 crore by CY30 at approximately 13 per cent CAGR — a substantial runway for all three business segments.
• POSHAN Abhiyaan, FSSAI's mandatory food fortification policy, and the government's focus on reducing anaemia and micronutrient deficiency provide structural tailwinds for both the premix (B2B2C) and therapeutic (ESG) segments without marketing spend.
• Branded B2C segment (currently 28.34 per cent of revenue in FY25) offers significantly higher margins relative to B2B2C premix; successful scale-up of PENTASURE, PEDIAGOLD, and NUTRONE could re-rate the blended margin profile materially.
   

Threats

• Heavy reliance on imported vitamins, minerals, and amino acids — approximately 61 per cent of revenue is from exports while key inputs are import-dependent — creates a dual foreign currency exposure (revenue upside vs. cost upside).
• The Nashik manufacturing facility is currently undergoing structural alterations pursuant to regulatory actions by the Sub-Divisional Magistrate, Dindori, which could cause temporary production disruption and order-fulfillment risk.
• Competitive intensity in the premix segment is rising from both global MNCs (DSM-Firmenich) with scale advantages and domestic players, while premium clinical nutrition faces competition from Abbott Healthcare, Nestlé, and Zydus Wellness.
• IPO is structured as a 100 per cent OFS; promoter shareholding reduces from approximately 79.10 per cent pre-IPO to approximately 56.92 per cent post-IPO, reflecting a significant liquidity exit that may weigh on near-term sentiment.

Financial Performance

All figures in Rs crore. Margins in per cent. Source: RHP (Restated Consolidated Financials).

Profit & Loss

Note: FY23 PAT includes Rs 3.59 crore of IPO-related expenses as an exceptional item, which suppressed reported PAT by approximately 38 per cent. Adjusting for this, underlying FY23 PAT would be approximately Rs 9.41 crore.

Balance Sheet

The balance sheet trajectory is constructive: total borrowings declined 48.7 per cent from Rs 51.87 crore in FY23 to Rs 26.60 crore in FY25, though a partial re-leveraging to Rs 39.79 crore in 9MFY26 warrants monitoring.

Peer Comparison

Source: RHP Peer Comparison Table (FY25 basis, as on March 31, 2025).

*P/E for Hexagon Nutrition Limited calculated at upper price band of Rs 45 divided by FY25 diluted EPS of Rs 1.75.

Notes: P/E Ratio for listed peers has been computed based on the closing market price of equity shares on the NSE on May 05, 2026, divided by the Diluted EPS for the year ended March 31, 2025. RoNW is computed as net profit after tax divided by the closing net worth.

Outlook & Relative Valuation

Avoid. Hexagon Nutrition operates in a structurally growing nutrition market and has delivered steady margin expansion over the last three years. However, the IPO lacks a compelling investment case at current valuations. The issue is a 100% Offer for Sale (OFS), resulting in no fresh capital infusion for capacity expansion, brand building, or business growth, thereby limiting the immediate strategic benefits of listing.

At the upper price band of ₹45, the company is valued at 25.7x FY25 earnings, while annualised 9MFY26 earnings imply a forward P/E of ~15.3x. Although the forward valuation appears reasonable relative to listed nutrition peers, the discount reflects Hexagon's smaller scale, lower brand strength, limited distribution reach, and modest earnings base. The company generated PAT of only ₹24.4 crore in FY25, and any meaningful re-rating will depend on its ability to consistently scale the higher-margin B2C branded portfolio, which currently contributes less than one-third of revenue.

While Hexagon Nutrition benefits from favourable long-term industry tailwinds, the current offering does not provide a sufficiently compelling margin of safety. The 100% OFS structure, modest earnings base, and execution-dependent growth trajectory constrain the near-term investment case despite reasonable run-rate valuations. Overall, we believe investors are better positioned to await greater earnings visibility and post-listing price discovery before considering exposure to the stock.